REPL · Replimune Group, Inc. · Webcasts, Transcripts & Audio
$14.59
+1.54 (+11.80%)
At close · Oct 28
Return incl. dividend (before tax)
Earnings today
Q2 2027 earnings call transcript
Going-concern doubt
— cleared Oct 28, 2026
The latest filing states the doubt was alleviated.
“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”View the 10-Q filed Oct 28, 2026
Market Cap
$1.21B
Shares
94.22M
Volume · Oct 28
2.5M
Avg daily vol (3M)
3.88M
Replimune Group, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Replimune Group, Inc. (REPL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY27 · Q2
2026-10-28
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Confident tone
Tudrakev commercial launch
Physician adoption and treatment workflows
Coverage and formulary access
Diluted EPS
$-0.54
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY27 · Q1
2026-08-14
Replimune Group, Inc. (REPL) Q1 2027 Earnings Call
Diluted EPS
$-0.72
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-05-22
Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
Confident tone
RP1 regulatory progress and PDUFA
Anti-PD-1 failed melanoma market opportunity
RP1 commercial launch preparation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2023-11-07
Replimune Group, Inc. (REPL) Q2 2024 Earnings Call
Diluted EPS
$-0.90
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-01-15
Replimune Group, Inc. (REPL) Q3 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–5 of 5 webcasts
Key facts
CIK
1737953
CUSIP
76029N106
13F (30d)
34 filings
34 filers
Visit website
Investor relations